GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Net-Net Working Capital

HBM Holdings (HKSE:02142) Net-Net Working Capital : HK$0.89 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

HBM Holdings's Net-Net Working Capital for the quarter that ended in Dec. 2024 was HK$0.89.

The industry rank for HBM Holdings's Net-Net Working Capital or its related term are showing as below:

HKSE:02142's Price-to-Net-Net-Working-Capital is ranked worse than
76.95% of 872 companies
in the Biotechnology industry
Industry Median: 4.04 vs HKSE:02142: 10.03

HBM Holdings Net-Net Working Capital Historical Data

The historical data trend for HBM Holdings's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Net-Net Working Capital Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial 3.45 1.64 0.40 0.76 0.89

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.66 0.76 0.93 0.89

Competitive Comparison of HBM Holdings's Net-Net Working Capital

For the Biotechnology subindustry, HBM Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HBM Holdings's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Price-to-Net-Net-Working-Capital falls into.


;
;

HBM Holdings Net-Net Working Capital Calculation

HBM Holdings's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1296.766+0.75 * 69.797+0.5 * 18.454-707.084
-0--3.07)/732.502
=0.89

HBM Holdings's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2024 is calculated as

Net-Net Working Capital(Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1296.766+0.75 * 69.797+0.5 * 18.454-707.084
-0--3.07)/732.502
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


HBM Holdings  (HKSE:02142) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


HBM Holdings Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Executives
Wang Jingsong 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Advantech Capital L.p.
Pang Kee Chan Hebert
Golden Link Investment Limited
Advantech Capital Partners Ltd.
Advantech Master Investment Limited
Astrazeneca Plc 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Owap Investment Pte Ltd 2101 Beneficial owner
Advantech Capital Holdings Ltd.
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

HBM Holdings Headlines

No Headlines